RU2019120008A - Композиция на основе rmp и способы ее применения - Google Patents
Композиция на основе rmp и способы ее применения Download PDFInfo
- Publication number
- RU2019120008A RU2019120008A RU2019120008A RU2019120008A RU2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A
- Authority
- RU
- Russia
- Prior art keywords
- rmp
- composition
- composition according
- paragraphs
- microns
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 238000000034 method Methods 0.000 title claims 7
- 210000003743 erythrocyte Anatomy 0.000 claims 6
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 4
- 229940022698 acetylcholinesterase Drugs 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010073391 Platelet dysfunction Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 229940125507 complex inhibitor Drugs 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 108010014806 prothrombinase complex Proteins 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical group OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (16)
1. Композиция, содержащая полученные из эритроцитов микрочастицы (RMP), демонстрирующая ацетилхолинэстеразную (AchE) активность, которая составляет менее 350 пмоль/мин/106 частиц/мкл.
2. Композиция по п. 1, в которой RMP демонстрирует ацетилхолинэстеразную (AchE) активность, которая составляет менее 200 пмоль/мин/106 частиц/мкл.
3. Композиция по п. 1 или 2, отличающаяся тем, что 20%-50% RMP в композиции содержит фосфатидилсерин.
4. Композиция по п. 3, отличающаяся тем, что 30%-45% RMP в композиции содержит фосфатидилсерин.
5. Композиция по любому из пп. 1-4, отличающаяся тем, что указанная композиция сокращает время до образования начального сгустка, которое определяют тромбоэластографией (ТЭГ) в цельной крови и плазме, по меньшей мере на две минуты.
6. Композиция по любому из пп. 1-5, отличающаяся тем, что средний диаметр RMP составляет примерно 0,40-0,6 мкм.
7. Композиция по п. 6, отличающаяся тем, что средний диаметр RMP составляет примерно 0,40-0,5 мкм.
8. Композиция по п. 7, отличающаяся тем, что средний диаметр RMP составляет примерно 0,47 мкм.
9. Композиция по любому из пп. 1-8, отличающаяся тем, что внутренняя плотность RMP составляет менее 3,5% внутренней плотности целых эритроцитов.
10. Композиция по п. 9, отличающаяся тем, что внутренняя плотность RMP составляет примерно 0,5-3,0% внутренней плотности целых эритроцитов, как определено сигналом бокового рассеяния поточной цитометрии.
11. Композиция по любому из пп. 1-10, отличающаяся тем, что RMP получены посредством продавливания эритроцитов через отверстие с получением разрушенных эритроцитов и дальнейшей фрагментации разрушенных эритроцитов путем бомбардировки на твердой поверхности.
12. Способ лечения чрезмерного кровотечения у субъекта, где указанный способ включает введение субъекту композиции по любому из пп. 1-11.
13. Способ по п. 12, отличающийся тем, что чрезмерное кровотечение вызвано тромбоцитопенией или дисфункцией тромбоцитов.
14. Способ по п. 13, отличающийся тем, что дисфункция тромбоцитов вызвана лекарственной терапией.
15. Способ по п. 12, отличающийся тем, что чрезмерное кровотечение вызвано антикоагулянтом.
16. Способ по п. 15, отличающийся тем, что антикоагулянт представляет собой кумадин, низкомолекулярный гепарин, ингибитор комплекса протромбиназы, ингибитор FXa или ингибитор тромбина.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428155P | 2016-11-30 | 2016-11-30 | |
| US62/428,155 | 2016-11-30 | ||
| PCT/US2017/063700 WO2018102409A2 (en) | 2016-11-30 | 2017-11-29 | Rmp composition and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019120008A true RU2019120008A (ru) | 2021-01-13 |
| RU2019120008A3 RU2019120008A3 (ru) | 2021-03-09 |
| RU2768743C2 RU2768743C2 (ru) | 2022-03-24 |
Family
ID=62241842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120008A RU2768743C2 (ru) | 2016-11-30 | 2017-11-29 | Композиция на основе rmp и способы ее применения |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11241457B2 (ru) |
| EP (1) | EP3548092B1 (ru) |
| JP (2) | JP7538600B2 (ru) |
| KR (2) | KR20190099436A (ru) |
| CN (1) | CN110799199B (ru) |
| AU (1) | AU2017367084B2 (ru) |
| BR (1) | BR112019010981A2 (ru) |
| CY (1) | CY1125462T1 (ru) |
| DK (1) | DK3548092T3 (ru) |
| ES (1) | ES2924134T3 (ru) |
| HR (1) | HRP20220892T1 (ru) |
| HU (1) | HUE059678T2 (ru) |
| IL (1) | IL266957B (ru) |
| LT (1) | LT3548092T (ru) |
| MX (1) | MX2019006354A (ru) |
| PL (1) | PL3548092T3 (ru) |
| PT (1) | PT3548092T (ru) |
| RS (1) | RS63537B1 (ru) |
| RU (1) | RU2768743C2 (ru) |
| SI (1) | SI3548092T1 (ru) |
| SM (1) | SMT202200380T1 (ru) |
| WO (1) | WO2018102409A2 (ru) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US5332578A (en) | 1989-04-14 | 1994-07-26 | Prp, Inc. | Platelet membrane microparticles |
| BR9505781A (pt) * | 1994-02-14 | 1996-03-05 | Kirin Brewery | Proteina tendo atividade TPO |
| US5690963A (en) | 1995-06-30 | 1997-11-25 | The United States Of America As Represented By The Secretary Of The Navy | Freeze dried red blood cells |
| DE69941031D1 (de) | 1998-11-12 | 2009-08-06 | Novolytics Inc | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion |
| US20030040480A1 (en) | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US7294455B2 (en) * | 2003-05-16 | 2007-11-13 | The University Of North Carolina At Chapel Hill | Fixed-dried platelets cross-linked to protein |
| US7811558B2 (en) | 2004-08-12 | 2010-10-12 | Cellphire, Inc. | Use of stabilized platelets as hemostatic agent |
| US9155764B1 (en) * | 2004-12-07 | 2015-10-13 | University Of Miami | Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding |
| ATE555799T1 (de) | 2004-12-07 | 2012-05-15 | Univ Miami | Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen |
| US20080057505A1 (en) | 2006-07-14 | 2008-03-06 | Ping Lin | Methods and compositions for detecting rare cells from a biological sample |
| US20130316011A1 (en) | 2011-01-28 | 2013-11-28 | University Of Miami | Expanded Utility of Red Cell-Derived Microparticles (RMP) for Treatment of Bleeding |
| WO2015069897A1 (en) * | 2013-11-07 | 2015-05-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Red blood cell membrane-derived microparticles and their use for the treatment of lung disease |
| US10722608B2 (en) * | 2015-03-04 | 2020-07-28 | University Of Rochester | Systemic and topical application of platelet microparticles to treat bleeding in trauma patients |
-
2017
- 2017-11-29 MX MX2019006354A patent/MX2019006354A/es unknown
- 2017-11-29 CN CN201780074200.3A patent/CN110799199B/zh active Active
- 2017-11-29 SM SM20220380T patent/SMT202200380T1/it unknown
- 2017-11-29 KR KR1020197018762A patent/KR20190099436A/ko not_active Ceased
- 2017-11-29 EP EP17876484.1A patent/EP3548092B1/en active Active
- 2017-11-29 JP JP2019529843A patent/JP7538600B2/ja active Active
- 2017-11-29 AU AU2017367084A patent/AU2017367084B2/en active Active
- 2017-11-29 BR BR112019010981A patent/BR112019010981A2/pt not_active Application Discontinuation
- 2017-11-29 SI SI201731199T patent/SI3548092T1/sl unknown
- 2017-11-29 HR HRP20220892TT patent/HRP20220892T1/hr unknown
- 2017-11-29 US US16/465,054 patent/US11241457B2/en active Active
- 2017-11-29 LT LTEPPCT/US2017/063700T patent/LT3548092T/lt unknown
- 2017-11-29 RU RU2019120008A patent/RU2768743C2/ru active
- 2017-11-29 KR KR1020247007757A patent/KR20240049569A/ko not_active Ceased
- 2017-11-29 ES ES17876484T patent/ES2924134T3/es active Active
- 2017-11-29 HU HUE17876484A patent/HUE059678T2/hu unknown
- 2017-11-29 WO PCT/US2017/063700 patent/WO2018102409A2/en not_active Ceased
- 2017-11-29 RS RS20220717A patent/RS63537B1/sr unknown
- 2017-11-29 PT PT178764841T patent/PT3548092T/pt unknown
- 2017-11-29 PL PL17876484.1T patent/PL3548092T3/pl unknown
- 2017-11-29 DK DK17876484.1T patent/DK3548092T3/da active
-
2019
- 2019-05-28 IL IL266957A patent/IL266957B/en unknown
-
2022
- 2022-08-03 CY CY20221100532T patent/CY1125462T1/el unknown
- 2022-10-28 JP JP2022173557A patent/JP2023017857A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markland Jr et al. | Snake venom metalloproteinases | |
| Wienkamp et al. | Platelets in the NETworks interweaving inflammation and thrombosis | |
| Semeraro et al. | Coagulopathy of acute sepsis | |
| Pryzdial et al. | Blood coagulation dissected | |
| Olsson et al. | NETosis in cancer–platelet–neutrophil crosstalk promotes tumor-associated pathology | |
| Seth et al. | Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model | |
| Ahmad et al. | Fibrin matrices: The versatile therapeutic delivery systems | |
| Ali et al. | Platelets: essential components of the immune system | |
| Frith et al. | Acute traumatic coagulopathy | |
| Sloos et al. | Platelet dysfunction after trauma: From mechanisms to targeted treatment | |
| Herbig et al. | Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear‐induced platelet activation | |
| US20140154234A1 (en) | Method for generating thrombin | |
| Gorbet et al. | Leukocyte activation and leukocyte procoagulant activities after blood contact with polystyrene and polyethylene glycol–immobilized polystyrene beads | |
| Pabinger et al. | Flamethrowers: blood cells and cancer thrombosis risk | |
| WO2010020423A3 (en) | Methods for treating bleeding disorders | |
| WO2008128149A3 (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| RU2019120008A (ru) | Композиция на основе rmp и способы ее применения | |
| RU2007138689A (ru) | Способ обработки призабойной зоны пласта | |
| WO2012017310A3 (en) | Protein fusion constructs possessing thrombolytic and anticoagulant properties | |
| Yu et al. | Effects of 6-(4-chlorophenoxy)-tetrazolo [5, 1-a] phthalazine on anticoagulation in mice and the inhibition of experimental thrombosis in rats | |
| NZ747528A (en) | Use of antiplatelet thrombolysin in the preparation of a medicament for treatment of thrombotic thrombocytopenic purpura | |
| RU2018121952A (ru) | Регулируемая кальцием активация тромбоцитов посредством электростимуляции | |
| Tripodi et al. | Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia | |
| WO2017136356A3 (en) | Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting | |
| FR3014319B1 (fr) | Preparations injectables a base de collagenes capables de controler les saignements et/ou de se substituer a des plaquettes dans le cas de syndromes hemorragiques |